Search Clinical Trials in the EU

Duration

11-15 visits

Phase

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

41-60 of 306 trials

Atypical Hemolytic Uremic Syndrome: Long-Term Study of Iptacopan

We are evaluating the long-term safety and effects of iptacopan in individuals with atypical hemolytic uremic syndrome. This study looks at how well the treatment works in preventing complications and improving kidney health.

Atypical Hemolytic Uremic Syndrome>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteNephrology

ZN-c3 for High-Grade Serous Ovarian Cancer

We are studying a new treatment called azenosertib for individuals with high-grade serous ovarian cancer. The trial aims to evaluate its safety and effectiveness, especially in patients with a specific genetic marker.

Ovarian, Fallopian Tube, and Peritoneal Cancer>2 yearsEfficacy phase (II)11-15 visits No Placebo Investigational Medicines Cost ReimbursementOncology

Follicular Lymphoma: Odronextamab vs. Rituximab

We are studying whether odronextamab combined with lenalidomide is safer and more effective than rituximab combined with lenalidomide for adults with relapsed or refractory follicular lymphoma and marginal zone lymphoma.

Marginal Zone LymphomaFollicular Lymphoma6-12 monthsConfirmation phase (III)11-15 visits No Placebo Standard Medicines Partially RemoteHematologyOncology

Chronic Hypoparathyroidism: Eneboparatide (AZP-3601)

We are studying a new medication to see if it helps people with chronic hypoparathyroidism manage their calcium levels and improve their physical symptoms. This trial compares the new treatment to a placebo to assess its effectiveness.

Hypoparathyroidism6-12 monthsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Partially RemoteEndocrinology

Alzheimer's Disease: PRI-002 Study

We are testing a new medication, PRI-002, for individuals with mild cognitive impairment or mild dementia due to Alzheimer's disease. The study aims to evaluate its safety and effectiveness in improving cognitive function.

Alzheimer's Disease1-2 yearsEfficacy phase (II)11-15 visits Investigational Medicines Cost ReimbursementNeurologyPsychiatry

Endometrial Cancer: RAINBO Treatment Study

We are exploring a new treatment approach for patients with endometrial cancer based on their molecular features. The goal is to see if this can improve survival rates and reduce the chance of cancer returning.

Mismatch Repair Deficient High-Risk Endometrial Cancer>2 yearsConfirmation phase (III)11-15 visits No Placebo Standard MedicinesGynecology and ObstetricsOncology

Metastatic Renal Cell Carcinoma: Treatment Comparison Study

We are comparing two treatment combinations for patients with metastatic renal cell carcinoma to see which one improves survival and quality of life. This study is for those who have not received treatment before and have specific risk factors.

Metastatic Renal Cell CarcinomaConfirmation phase (III)11-15 visits No Placebo Standard MedicinesInternal MedicineOncology

Oligometastatic Non-Small Cell Lung Cancer: Immunotherapy with Local Treatments

We are studying whether adding a local treatment to standard immunotherapy helps improve survival for patients with oligometastatic non-small cell lung cancer. This trial will also look at quality of life and side effects.

Synchronous Oligometastatic Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)11-15 visits No Placebo Standard MedicinesOncologyPulmonology

Sjögren’s Syndrome: Deucravacitinib Study

We are testing a new medication, deucravacitinib, for adults with active Sjögren’s Syndrome to see if it improves symptoms better than a placebo. The study also looks at the safety and tolerability of this treatment.

Sjogren's Syndrome1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Standard Medicines Cost ReimbursementRheumatology

Chronic Lung Allograft Dysfunction: Belumosudil Tablets

We are testing belumosudil tablets to see if they improve lung function in adults with chronic lung allograft dysfunction after lung transplantation. The study will also look at how this treatment affects exercise capacity and overall health.

Lung Transplant Rejection6-12 monthsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicinePulmonology

Cholestatic Pruritus: Linerixibat Treatment Study

We are studying the long-term safety and tolerability of linerixibat for people with cholestatic pruritus due to primary biliary cholangitis. The trial also looks at how this treatment affects quality of life and itch relief.

Cholestatic PruritusPrimary Biliary Cholangitis1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementGastroenterologyHepatology

Pulmonary Arterial Hypertension: Seralutinib Inhalation Study

We are studying whether inhaling seralutinib helps improve exercise capacity in people with pulmonary arterial hypertension. The trial also looks at safety and other health benefits compared to a placebo.

Pulmonary Arterial Hypertension1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementCardiologyPulmonology

Chronic Cutaneous Lupus Erythematosus: Anifrolumab Study

We are investigating whether anifrolumab can improve skin symptoms in adults with chronic cutaneous lupus erythematosus who haven't responded to other treatments. The study will compare its effects to a placebo over 24 weeks.

Cutaneous Lupus Erythematosus1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Standard Medicines Cost Reimbursement Partially RemoteDermatologyRheumatology

Heart Failure and Obesity: Weight Loss with Semaglutide

We are investigating whether weight loss using semaglutide is more effective than a calorie-restricted diet in improving physical performance for patients with heart failure and obesity. The study also looks at quality of life and heart health impacts from both weight loss methods.

Heart Failure with Reduced Ejection FractionObesity1-2 yearsEfficacy phase (II)11-15 visits No Placebo Investigational Medicines Partially RemoteCardiologyDiabetologyEndocrinology

Splenic Marginal Zone Lymphoma: Rituximab with Zanubrutinib

We are comparing the effects of adding zanubrutinib to rituximab versus using rituximab alone in patients with untreated splenic marginal zone lymphoma. The goal is to see if the combination improves survival and response rates.

Splenic Marginal Zone Lymphoma>2 yearsConfirmation phase (III)11-15 visits No Placebo Standard MedicinesOncology

Post-Menopausal Osteoporosis: BP16 vs. EU-Prolia

We are comparing a new treatment, BP16, to EU-Prolia for women with post-menopausal osteoporosis. The study looks at how well each treatment improves bone health and their safety.

Post-Menopausal Osteoporosis1-2 yearsConfirmation phase (III)11-15 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteEndocrinologyRheumatology

Growth Hormone Deficiency: LUM-201 Treatment Study

We are monitoring the long-term safety of LUM-201 in children with idiopathic growth hormone deficiency. This study also looks at how the treatment affects growth and related health markers.

Idiopathic Growth Hormone Deficiency>2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Investigational MedicinesEndocrinologyPediatrics

Guselkumab for Crohn's Disease Healing

We are studying whether guselkumab can help heal the intestinal wall in patients with Crohn's disease. This research aims to find out how effective it is over 48 weeks.

Crohn's Disease>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteGastroenterologyInternal Medicine

Alectinib for Pediatric ALK Fusion-Positive Tumors

We are studying the safety and effectiveness of alectinib in children with solid or CNS tumors that have not responded to other treatments. This trial aims to find the best dose and understand how the drug works in young patients.

Malignant Mast Cell TumorsALK Fusion-Positive Tumors>2 yearsSafety phase (I)Efficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteOncologyPediatrics

Alpelisib for Lymphatic Malformations with PIK3CA Mutation

We are studying whether alpelisib can improve symptoms and imaging results in adults and children with lymphatic malformations caused by a PIK3CA mutation. Participants will be compared to those receiving a placebo to assess the treatment's effectiveness.

Lymphangioma>2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteHematologyOncology

Search Clinical Trials in the European Union